Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1659-1665

  Kang, Seongeun ^a   Kim, Byungtak ^a   Park, Sung Bin ^a   Jeong, Gookjoo ^a   Kang, Han Sung ^b   Liu, Ran ^c   Kim, Sun Jung ^a  

^a Dongguk University   (South Korea)

^b National Cancer Center   (South Korea)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

5 aza 2' deoxycytidine; Breast cancer; Cancer stage; Genome wide methylation; NEFL

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CELL LINE; CLINICAL ARTICLE; CLUSTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE ACTIVITY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION;

BREAST; BREAST NEOPLASMS; CELLS, CULTURED; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASM STAGING; NEUROFILAMENT PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84885082950     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2094     Document Type: Article

References (31)

1. Pare R, Yang T, Shin JS and Lee CS: The significance of the senescence pathway in breast cancer progression. J Clin Pathol 66: 491-495, 2013.
2. Harburg GC and Hinck L: Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes. J Mammary Gland Biol Neoplasia 16: 257-270, 2011.
3. Shi L, Sun L, Li Q, et al: Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 108: 7541-7546, 2011.
4. Krell J, Frampton AE, Jacob J, Castellano L and Stebbing J: miRNAs in breast cancer: ready for real time? Pharmacogenomics 13: 709-719, 2012.
5. Kang JH, Kim SJ, Noh DY, et al: Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 81: 573-579, 2001.
6. Yan PS, Shi H, Rahmatpanah F, et al: Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 63: 6178-6186, 2003.
7. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD and Richardson AL: BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91: 179-186, 2005.
8. Faryna M, Konermann C, Aulmann S, et al: Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 26: 4937-4950, 2012.
9. Van Hoesel AQ, Sato Y, Elashoff DA, et al: Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer 108: 2033-2038, 2013.
10. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al: Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 116: 407-414, 2005.
11. Chen ST, Lin SY, Yeh KT, et al: Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med 14: 577-582, 2004.
12. Hu M, Yao J, Cai L, et al: Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37: 899-905, 2005.
13. Sebova K, Zmetakova I, Bella V, et al: RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 10: 13-26, 2011.
14. Mohammad J, Zeerak A and Hjerten S: Dye-ligand affinity chromatography on continuous beds. Biomed Chromatogr 9: 80-84, 1995.
15. Jeschke J, Van Neste L, Glockner SC, et al: Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7: 701-709, 2012.
16. Fernandez SV, Snider KE, Wu YZ, Russo IH, Plass C and Russo J: DNA methylation changes in a human cell model of breast cancer progression. Mutat Res 688: 28-35, 2010.
17. Loss LA, Sadanandam A, Durinck S, et al: Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics 11: 305, 2010.
18. Kim JH, Kang HS, Kim TW and Kim SJ: Differential methylation hybridization profiling identifies involvement of STAT1-mediated pathways in breast cancer. Int J Oncol 39: 955-963, 2011.
19. Wee EJ, Peters K, Nair SS, et al: Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 31: 4182-4195, 2012.
20. Fackler MJ, Umbricht CB, Williams D, et al: Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71: 6195-6207, 2011.
21. Bonazzi VF, Irwin D and Hayward NK: Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes Cancer 48: 10-21, 2009.
22. Wloga D, Webster DM, Rogowski K, et al: TTLL3 is a tubulin glycine ligase that regulates the assembly of cilia. Dev Cell 16: 867-876, 2009.
23. Abe A, Numakura C, Saito K, et al: Neurofilament light chain polypeptide gene mutations in Charcot-Marie-Tooth disease: nonsense mutation probably causes a recessive phenotype. J Hum Genet 54: 94-97, 2009.
24. Li XQ, Li L, Xiao CH and Feng YM: NEFL mRNA expression level is a prognostic factor for early-stage breast cancer patients. PLoS One 7: e31146, 2012.
25. Shen L, Kondo Y, Guo Y, et al: Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 3: 2023-2036, 2007.
26. Sincic N and Herceg Z: DNA methylation and cancer: ghosts and angels above the genes. Curr Opin Oncol 23: 69-76, 2011.
27. Carmona FJ and Esteller M: DNA methylation in early neoplasia. Cancer Biomark 9: 101-111, 2010.
28. Seitz S, Werner S, Fischer J, Nothnagel A, Schlag PM and Scherneck S: Refined deletion mapping in sporadic breast cancer at chromosomal region 8p12-p21 and association with clinicopathological parameters. Eur J Cancer 36: 1507-1513, 2000.
29. Chen B, Chen J, House MG, Cullen KJ, Nephew KP and Guo Z: Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res 10: 305-315, 2012.
30. Fumagalli C, Pruneri G, Possanzini P, et al: Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 134: 131-137, 2012.
31. Li L, Lee KM, Han W, et al: Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet 19: 4273-4277, 2010.